AFT Pharmaceuticals (ASX:AFP) Additional Paid-In Capital: A$0.0 Mil(As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
76 GF Score
Price A$3.86
GF Value A$3.37
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Additional Paid-In Capital?

AFT Pharmaceuticals ASX:AFP -0.26% 76 Additional Paid-In Capital is A$0.0 Mil as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 76/100 and a GF Value™ of A$3.37 (Modestly Overvalued). The stock has 6 warning signs investors should review.


AFT Pharmaceuticals Additional Paid-In Capital Related Terms

AFT Pharmaceuticals Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Additional Paid-In Capital Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:AFP
76GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of A$0.0 Mil mean?
AFT Pharmaceuticals (ASX:AFP) has a Additional Paid-In Capital of A$0.0 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Additional Paid-In Capital too high?
AFT Pharmaceuticals' current Additional Paid-In Capital is A$0.0 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Additional Paid-In Capital compare to ZTS and UTHR?
AFT Pharmaceuticals' Additional Paid-In Capital of A$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Additional Paid-In Capital is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.37, compared to a current price of A$3.86 — trading 14.5% above its estimated fair value. The current Additional Paid-In Capital is A$0.0 Mil. AFT Pharmaceuticals' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Additional Paid-In Capital is A$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued. The current stock price of A$3.86 is trading 14.5% above its estimated GF Value™ of A$3.37. GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ASX:AFP:

  • Additional Paid-In Capital: A$0.0 Mil
  • GF Value™: A$3.37 vs. price of A$3.86 (14.5% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
76GF Score

Get the complete analysis for ASX:AFP

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.86
Price
A$3.37
GF Value